Cargando…
Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03
BACKGROUND: Neutropenia is a common adverse reaction of chemotherapy. We assessed whether chemotherapy-induced neutropenia could be a predictor of survival for patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 387 chemotherapy-naïve patients who received chemotherapy (vinorelbine...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778518/ https://www.ncbi.nlm.nih.gov/pubmed/19862000 http://dx.doi.org/10.1038/sj.bjc.6605348 |
_version_ | 1782174257794514944 |
---|---|
author | Kishida, Y Kawahara, M Teramukai, S Kubota, K Komuta, K Minato, K Mio, T Fujita, Y Yonei, T Nakano, K Tsuboi, M Shibata, K Atagi, S Kawaguchi, T Furuse, K Fukushima, M |
author_facet | Kishida, Y Kawahara, M Teramukai, S Kubota, K Komuta, K Minato, K Mio, T Fujita, Y Yonei, T Nakano, K Tsuboi, M Shibata, K Atagi, S Kawaguchi, T Furuse, K Fukushima, M |
author_sort | Kishida, Y |
collection | PubMed |
description | BACKGROUND: Neutropenia is a common adverse reaction of chemotherapy. We assessed whether chemotherapy-induced neutropenia could be a predictor of survival for patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 387 chemotherapy-naïve patients who received chemotherapy (vinorelbine and gemcitabine followed by docetaxel, or paclitaxel and carboplatin) in a randomised controlled trial were evaluated. The proportional-hazards regression model was used to examine the effects of chemotherapy-induced neutropenia and tumour response on overall survival. Landmark analysis was used to lessen the bias of more severe neutropenia resulting from more treatment cycles allowed by longer survival, whereby patients who died within 126 days of starting chemotherapy were excluded. RESULTS: The adjusted hazard ratios for patients with grade-1 to 2 neutropenia or grade-3 to 4 neutropenia compared with no neutropenia were 0.59 (95% confidence interval (CI), 0.36–0.97) and 0.71 (95% CI, 0.49–1.03), respectively. The hazard ratios did not differ significantly between the patients who developed neutropenia with stable disease (SD), and those who lacked neutropenia with partial response (PR). CONCLUSION: Chemotherapy-induced neutropenia is a predictor of better survival for patients with advanced NSCLC. Prospective randomised trials of early-dose increases guided by chemotherapy-induced toxicities are warranted. |
format | Text |
id | pubmed-2778518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27785182010-11-03 Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 Kishida, Y Kawahara, M Teramukai, S Kubota, K Komuta, K Minato, K Mio, T Fujita, Y Yonei, T Nakano, K Tsuboi, M Shibata, K Atagi, S Kawaguchi, T Furuse, K Fukushima, M Br J Cancer Clinical Study BACKGROUND: Neutropenia is a common adverse reaction of chemotherapy. We assessed whether chemotherapy-induced neutropenia could be a predictor of survival for patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 387 chemotherapy-naïve patients who received chemotherapy (vinorelbine and gemcitabine followed by docetaxel, or paclitaxel and carboplatin) in a randomised controlled trial were evaluated. The proportional-hazards regression model was used to examine the effects of chemotherapy-induced neutropenia and tumour response on overall survival. Landmark analysis was used to lessen the bias of more severe neutropenia resulting from more treatment cycles allowed by longer survival, whereby patients who died within 126 days of starting chemotherapy were excluded. RESULTS: The adjusted hazard ratios for patients with grade-1 to 2 neutropenia or grade-3 to 4 neutropenia compared with no neutropenia were 0.59 (95% confidence interval (CI), 0.36–0.97) and 0.71 (95% CI, 0.49–1.03), respectively. The hazard ratios did not differ significantly between the patients who developed neutropenia with stable disease (SD), and those who lacked neutropenia with partial response (PR). CONCLUSION: Chemotherapy-induced neutropenia is a predictor of better survival for patients with advanced NSCLC. Prospective randomised trials of early-dose increases guided by chemotherapy-induced toxicities are warranted. Nature Publishing Group 2009-11-03 2009-09-29 /pmc/articles/PMC2778518/ /pubmed/19862000 http://dx.doi.org/10.1038/sj.bjc.6605348 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Kishida, Y Kawahara, M Teramukai, S Kubota, K Komuta, K Minato, K Mio, T Fujita, Y Yonei, T Nakano, K Tsuboi, M Shibata, K Atagi, S Kawaguchi, T Furuse, K Fukushima, M Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 |
title | Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 |
title_full | Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 |
title_fullStr | Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 |
title_full_unstemmed | Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 |
title_short | Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03 |
title_sort | chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from japan multinational trial organization lc00-03 |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778518/ https://www.ncbi.nlm.nih.gov/pubmed/19862000 http://dx.doi.org/10.1038/sj.bjc.6605348 |
work_keys_str_mv | AT kishiday chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT kawaharam chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT teramukais chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT kubotak chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT komutak chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT minatok chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT miot chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT fujitay chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT yoneit chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT nakanok chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT tsuboim chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT shibatak chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT atagis chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT kawaguchit chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT furusek chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 AT fukushimam chemotherapyinducedneutropeniaasaprognosticfactorinadvancednonsmallcelllungcancerresultsfromjapanmultinationaltrialorganizationlc0003 |